Whilst preclinical work has validated MCL-1 as a relevant target in breast cancer, the essentiality of MCL-1 in many normal cell types may necessitate careful administration of MCL-1 targeting drugs to facilitate a therapeutic window. This evidence concerns the gene MCL1 and breast carcinoma.